1	Superior long-term patency of no-touch vein graft compared to conventional vein grafts
2	in over 1500 consecutive patients
3	
4	
5	Gabriele Ferrari, MD ^{1, 2} , Richard Loayza, MD ¹ , Ava Azari, MD ¹ , Håkan Geijer, MD, PhD ³ ,
6	Yang Cao, PhD ⁴ , Roland Carlsson, MD, PhD ⁵ , Leif Bojö, MD, PhD ⁶ , Ninos Samano, MD,
7	PhD ¹ , Domingos Souza, MD, PhD ¹
8	
9	¹ University Health Care Research Centre, Faculty of Medicine and Health, Örebro
10	University, Örebro, Sweden; ² Department of Cardiology and Cardiothoracic Surgery,
11	Blekinge Hospital, Karlskrona, Sweden; ³ Department of Radiology, Faculty of Medicine and
12	Health, Örebro University, Örebro, Sweden; ⁴ Clinical Epidemiology and Biostatistics, School
13	of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden;
14	⁵ Svensk PCI AB, Regional Hospital of Karlstad, Karlstad, Sweden; ⁶ Clinical Physiology
15	Division, Regional Hospital of Karlstad, Karlstad, Sweden.
16	
17	Short title: Patency of no-touch and conventional vein grafts
18	
19	Corresponding author: Dr. Gabriele Ferrari
20	Address: Department of Cardiology and Cardiothoracic surgery, Blekinge Hospital, 37181
21	Karlskrona, Sweden.
22	Office: +46 455736897
23	Fax: +46 455731051
24	E-mail: gabriele.ferrari@regionblekinge.se
25	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 ABSTRACT

- 27 **Objectives:** To evaluate the long-term angiographic patency of saphenous vein grafts (SVG)
- 28 harvested using the no-touch technique compared to the conventional technique.
- 29 Methods: This was a single-center, retrospective, cohort study. The inclusion criteria were
- 30 individuals who underwent a CABG (coronary artery bypass grafting) between January 1995
- 31 and July 2020, and who successively needed a clinically-driven angiography. The primary
- 32 endpoint was long-term patency. The secondary endpoints were differences in patency based
- 33 on sub-group analysis (single vs. sequential graft, divided by target vessel).
- Results: The study included 1520 individuals (618 no-touch, 825 conventional and 77
 arterial grafts). The mean clinical follow-up time was 8.4 years ± 5.5 years. The patency per
 patient was 70.7% in the no-touch grafts vs. 46.7% in the conventional grafts (p < 0.001, OR
 = 2.8). The graft patency was 75.9% in the no-touch grafts vs. 62.8% in the conventional
 grafts (p < 0.001, OR= 1.8).
 Conclusions: The no-touch vein grafts were associated with statistically significantly higher
- 40 patency at long-term compared to the conventional grafts.
- 41
- 42 Clinical Trial Registration: NCT04656366, 7 December 2020

44 Non-standard abbreviations and non-standard acronyms

- 45 A: arterial graft
- 46 BMS: bare metal stent
- 47 C: conventional
- 48 CABG: coronary artery bypass grafting
- 49 DA: diagonal artery
- 50 DAPT: double antiplatelet therapy
- 51 DES: drug-eluting stent
- 52 EF: ejection fraction
- 53 FFR: fractional flow reserve
- 54 iFR: instantaneous wave-free ratio
- 55 IQR: interquartile range
- 56 LAD: left anterior descending artery
- 57 LITA: left internal thoracic artery
- 58 MA: marginal artery
- 59 MACE: major adverse cardiac events
- 60 MI: myocardial infarction
- 61 NT: no-touch
- 62 OR: odds ratio
- 63 PCI: percutaneous coronary intervention
- 64 RCA: right coronary artery
- 65 RITA: right internal thoracic artery
- 66 SD: standard deviation
- 67 SVG: saphenous vein graft
- 68 TIMI: thrombolysis in myocardial infarction
- 69 TVR: target vessel revascularization

70 Clinical Perspective

71 - What is new?

- 72 > The largest follow-up of the patency of no-touch vein grafts in the
 73 international literature.
- Patients with a no-touch vein graft had significantly better patency (p < 0.001)
 at mean follow-up of more than 8 years.

76 - What are the clinical implications?

- 77 Consequent reduction in cardiovascular events after no-touch vein graft.
- 78 > Benefits at individual level due to fewer episodes of re-angina and myocardial
 79 infarction, and fewer coronary interventions.
- 80 > Benefits at community level due to fewer re-hospitalizations and a reduction
 81 in healthcare costs.

83 Introduction

84 Ischemic heart disease is the leading cause of death worldwide, accounting for almost 8.9 million deaths in 2019¹. The main treatment options are percutaneous coronary intervention 85 (PCI), coronary artery bypass grafting (CABG) and, in some cases, both. The choice of 86 treatment depends on the clinical presentation, grade of disease, type of lesion, and patient 87 comorbidities. Guidelines ²⁻⁴ recommend CABG in cases of multivessel disease or left main 88 89 stem, and/or diabetes mellitus, to improve survival and reduce the risk of major adverse cardiac events (MACE)⁵⁻⁹, which are defined as death, myocardial infarction (MI), in-stent 90 restenosis, and/or repeated target vessel revascularization (TVR). The grafts used, especially 91 92 vein grafts, are subject to remodelling and progressive intimal hyperplasia and 93 atherosclerosis, which may lead to graft stenosis or occlusion and thereby limit the graft patency⁷. These events occur more frequently and rapidly in saphenous vein grafts (SVGs) 94 compared to left internal thoracic artery (LITA) or other arterial grafts^{8,9}. Graft patency after 95 CABG is a major determinant of clinical prognosis and long-term survival⁷. 96

97 The no-touch (NT) technique ¹⁰ differs from the conventional technique in that it is associated 98 with less endothelium damage during the harvesting procedure ^{11, 12} and leads to reduced neo-99 intimal hyperplasia and subsequent atherosclerosis in the long term ^{13, 14}.

The aim of this study was to evaluate the long-term angiographic patency of saphenous vein
grafts (SVG) harvested using the NT technique compared to the conventional technique.

This is a single-center, retrospective, cohort study. The study complied with the STROBE
(STrengthening the Reporting of OBservational studies in Epidemiology) statement and the
STROBE checklist was used ¹⁵.

106 Material and Methods

107 Data collection

This single-center study included all individuals treated with a CABG between January 1, 109 1995 and June 30, 2020 at our Cardiothoracic Department and who successively needed a 110 clinically driven-angiography. The study was a single-center study involving a center with 111 long experience with the NT technique having used it for harvesting the saphenous vein since 112 1990. The study was performed in accordance with the Declaration of Helsinki. The Regional 113 Ethical Review Board approved the study (Dnr 2020/04168).

114 The standard operation in our center has been to anastomise the LITA to the LAD (left 115 anterior descending) and vein grafts to the other target vessels; in some cases, total arterial revascularization (A) occurred. The SVG was harvested either with the NT or with the C 116 technique, as previously described ¹⁶. The type of technique used was chosen by the surgeon 117 118 at the time of operation based on individual assessment and, therefore, without 119 randomization. The angiographies were performed in two cardiology departments and were 120 clinically driven, being due to either angina or myocardial infarction. No planned 121 angiographic follow-up was performed. No exclusion criterion was defined.

122 The grade of stenosis and its significance was defined according to the 2021 American Heart 123 Association for coronary artery revascularization ¹⁷. A limit of 70% was set for the non-left 124 main stenosis and 50% for the left main stenosis or for graft stenosis; in case of doubt, the 125 severity of the lesion was confirmed using the FFR (fractional flow reserve) or the iFR 126 (instantaneous wave-free ratio).

127 The operative data (CABG) and the procedural data were collected with the help of an

128 intervention-related quality register (the Swedish cardiological and cardiosurgical

129 intervention register Swedeheart)¹⁸. The operative data regarding the type of vein graft, the

130 number of anastomoses, and the target vessel for the peripheral anastomosis were extracted

131 and double checked by reviewing records in the clinical software of the two hospitals

132 involved.

133

134 Statistical methods

135 The primary endpoint was defined as long-term patency.

136 Secondary outcomes were the differences between single grafts and sequential grafts, and the

137 different territories fed by the stenosed vein graft based on sub-group analyses.

138 Descriptive statistics were calculated as means ± standard deviations (SD) for normally

139 distributed variables, as median with interquartile range (IQR) for non-normally distributed

140 variables, and as count with percentage for categorical variables.

141 The Chi-squared test (or Fisher's exact test for an expected count lower than 5) was used to

142 compare categorical proportions between the two groups (NT and C). The unpaired t-test was

143 performed to compare continuous variables and the Mann-Whitney U-test was used in cases

144 of non-normally distributed data.

145 Statistical analyses were performed using SPSS version 27.0 (IBM, Armonk, NY, USA).

146

147 **Results**

Between January 2006 and July 2020, 1571 individuals who had previously been treated with CABG needed an angiography (Figure 1). Fifty-one were lost at follow-up due to the inability to access the surgical reports (i.e., microfilm not available, journal lost, data protection).

The study included 1520 consecutive patients (618 NT, 825 C, 77 A) who needed a postoperative angiography (see Figure 1 and Table 1) with a mean follow-up time of $8.4 \pm$ 5.5 years and up to 24.7 years. The study analysed 2564 venous grafts (908 NT, 1656 C), Table 2.

156 In 29 cases, the angiography was only diagnostic and no new stenosis was detected. In 614

157 cases, stenoses were present in at least one vein graft. One hundred and thirty individuals 158 presented with a stenosis in an arterial graft, and in 747 cases the new stenosis affected only 159 the native vessels.

160

161 Demographic, operative, and procedural characteristics

162 A total of 1443 individuals received an SVG at surgery (618 NT, 825 C). The demographic, operative and angiographic characteristics of this group are summarized in Table 3. The 163 demographic characteristics of the two groups were similar and patients had a comparable 164 age at the time of CABG (63.2 ± 8.6 years NT, 63.1 ± 21.1 years C; p = 0.893; Table 3); most 165 166 of the patients were male (78.5%). The risk factor distribution showed a significantly higher 167 rate of hypertension (89% NT vs. 83.3% C) and hypercholesterolemia (91.7% NT vs. 84% C) 168 in the NT group (p < 0.001). Fewer patients with an NT SVG received a post-operative 169 DAPT (dual anti platelet therapy), 35.4% NT vs. 44% C (p = 0.001). 170 The operative characteristics regarding number of peripheral anastomoses were similar in the

171 two groups (Table 4). No differences regarding the indication for the new angiography were

172 presented (p = 0.916), Table 4.

173 The mean follow-up time was 5.5 \pm 4.4 years for the individuals with an NT SVG and 10.7 \pm

- 174 5.1 years for the individuals with a C SVG.
- 175
- 176 Clinical follow-up
- 177 Primary endpoint

178 The total patency rate per patient was 70.7% (437/618) in the NT group and 46.7% (385/825)

- in the C group (p < 0.001), with an OR (odds ratio) of 2.8, Table 5.
- 180 The patency rate per graft was 75.9% (609/908) in the NT group and 63.5% (1051/1656) in
- 181 the C group (p < 0.001), with an OR of 1.8, Table 6.
- 182

183 <u>Secondary endpoint</u>

184 Single grafts vs. sequential grafts

In the analysis of the different types of graft received (single or sequential), there was a statistically significant higher patency in the NT group both for single grafts (75.6% NT vs. 62.8% C, p < 0.001) and for sequential grafts (76.0% NT vs. 65.3% C, p < 0.001), Table 6.

- 188
- 189 *Territories fed by the stenosed vein graft*

190 The subgroup analysis, divided by distal anastomosis, revealed statistically significantly 191 better results for the NT grafts for each of the different distribution territories, Table 7. The 192 patency of the NT SVGs was over 80% if the target vessel was a coronary of the left system, 193 and around 70% if the target vessel was the right coronary artery (RCA). In contrast, the 194 patency of the C SVGs was as low as 57% if the target vessel was the RCA, and never 195 reached 80% in the left system. The differences between the NT and the C in the four 196 different territories of distribution were significant even when analysing the single and the 197 sequential grafts separately; however, the exceptions were the single grafts to the marginal artery (MA), the sequential ones to RCA, and both types to the left anterior descending 198 199 (LAD) due to the limited number of included individuals, Table 7.

200

201 Patency of arterial grafts

The long-term patency of the total arterial grafts was 86.3% and of the LITA grafts 96.2%. The patency rates for arterial grafts were similar regardless of whether the patients received an SVG or not, Table 5.

205

206

207 Discussion

208 This study presents the results from the largest long-term follow-up investigation of the

209 patency of NT SVGs.

The main finding of this study was higher graft patency at follow-up of the NT grafts (75.9%), compared to the C grafts (63.5%); p < 0.001. The superiority of the NT SVG was shown even when the different types of grafts (single vs. sequential) and the different types of territory of distribution were analysed. It has to be mentioned that NT grafts have shorter follow-up compared to the C grafts; however, this is due to higher rates of restenosis in the native vessels and not in the SVGs themselves.

216

217 It is known that C SVGs have high risks of thrombosis, intimal hyperplasia, and early 218 atherosclerosis, which all lead to graft occlusion rates of up to 50-60% after 10 years, 219 according to most clinical records ¹⁹⁻²¹.

Our study showed similar results for the C grafts with a patency per patient of only 46.7% at a mean follow-up of 8.4 years. The NT grafts, on the other hand, present a patency per patient of more than 70% at follow-up (OR of 2.8) and of almost 76% per graft.

Several studies ^{11, 13, 14, 16, 22-25} have shown the superiority of NT SVGs compared to C SVGs on follow-up at a mean time up to 16 years ¹⁴. Previous studies have, however, had either a limited follow-up time of maximum 1 year ^{22, 23, 25} or included a limited number of patients (fewer than 300) ^{11, 13, 14, 16, 23, 24}. The present study is the first to include both a large cohort, more than 1500 individuals, and a mean follow-up time of more than 5 years and up to almost 25 years. The higher long-term patency of NT SVGs may play an important role in reduced long-term MACE and re-hospitalization rates.

230

In our previous study ²⁶ we noted a very limited number of patients with NT SVGs being treated with PCI compared to C (63 NT vs. 246 C). We also noted that almost 70% of patients who needed a coronary angiography after the CABG operation did not receive a PCI on their vein graft. The present study gives an explanation for these observations; more than

half (57.6%) of the patients with an NT SVG who needed a postoperative angiography did
not have a SVG stenosis, but presented with a new stenosis in the native vessels. This
occurred in only 39.6% of patients with a C SVG.

Another interesting data is the higher percentage of sequential grafts in the NT group (49.3% vs. 24.7%). This is possible thanks to the qualities of the NT grafts that are much less prone to kinking when performing multiple anastomoses ¹², comparing the C technique.

241

242 As previously mentioned, NT grafts have a shorter time to follow-up compared to C grafts, 243 with only 23 cases (vs. 124) needing an angiography more than 15 years after the operation. 244 This shorter follow-up time for NT grafts is due to a lower patency rate of native vessels in 245 these individuals. A possible explanation is the statistically significant difference (35.4% vs 246 44.0%, p = 0.001) in the use of DAPT, with NT grafts receiving postoperative DAPT in 247 fewer cases compared to C grafts. The benefits of DAPT after an acute coronary syndrome, 248 in terms of reduced risk of restenosis and higher short- and long-term patency rates, are well known and supported by the international guidelines ²⁷. Another possible explanation is that 249 250 in the 1990's, the C graft was used in most cases so these patients automatically have a longer 251 follow-up time than the NT grafts.

252

The main limitation of this study is that it is non-randomized and the choice of graft type was dependent on the surgeon's choice. Another limitation is the different follow-up times in the two groups.

256

257 Conclusions

The results regarding the NT SVGs are encouraging, with statistically significantly higher patency at long-term follow-up compared to a C SVG, and with an almost 50% reduction in cases of vein graft stenosis long-term.

The results suggest an important reduction of cardiovascular events if the patients receive
comparable medical treatment post-surgery and if the management of the risk factors follows
the guidelines.
Randomized studies are needed to evaluate the performance and benefits of NT SVGs at both
individual (better patency and fewer coronary interventions) and community (fewer rehospitalizations) levels.

268	Acknowledgements: We thank research assistant Ulf Graf for help with the database
269	settings.
270	
271	Sourcing of Fundings: This work was supported by Region Örebro County through the
272	regional research board (grant OLL- OLL-935188, 18 January 2020).
273	
274	Disclosures: None.
275	
276	Supplementary Files
277	Supplementary Table S1
278	Supplementary Table S2
279	Supplementary Table S3
280	
281	Author contribution statement
282	Gabriele Ferrari, Håkan Geijer, Ninos Samano, Domingos Souza, Roland Carlsson and Leif
283	Bojö devised the original concept of this study. Gabriele Ferrari, Håkan Geijer, Ninos
284	Samano, Domingos Souza, Roland Carlsson and Leif Bojö designed the study. Gabriele
285	Ferrari, Richard Loayza and Ava Azari collected the patient data. Gabriele Ferrari, Richard
286	Loayza and Ava Azari performed the statistical analysis. Yang Cao provided support for
287	statistical analysis and result explanation. Gabriele Ferrari, and Yang Cao wrote the first draft
288	of the manuscript. All authors reviewed the manuscript, contributed significantly to its critical
289	review, and approved the final version.

291 Figure legends

292 Figure 1: STROBE flowchart of the individuals included in the study

294	Table 1: Graft characteristics	of the patients in	the total population
		1	1 1

Patient characteristics	N (%)
No-touch	618 (40.7)
Conventional	825 (54.3)
LITA to LAD	1273 (83.8)
RITA or Radial	144 (9.5)
Total Arterial	77 (5.1)
No-touch single grafts	203 (13.4)
No-touch sequential grafts	415 (27.3)
Conventional single grafts	450 (29.6)
Conventional sequential grafts	375 (24.7)

296 Table 2: Vein graft characteristics of the two groups

Patient characteristics	No-touch	Conventional
No. total grafts	908	1656
No. single grafts	463	1247
No. sequential grafts	445	409

Patient characteristics	No-touch	Conventional	p-value
No. of patients, n (%)	618 (40.7)	825 (54.3)	
Mean age at CABG, years \pm SD	63.2 ± 8.6	63.1 ± 21.1	0.893
Male, n (%)	506 (81.9)	626 (75.9)	0.006
Hypertension, n (%)	550 (89.0)	687 (83.3)	< 0.001
Hypercholesterolemia, n (%)	567 (91.7)	693 (84.0)	< 0.001
Diabetes mellitus, n (%)	216 (39.8)	284 (34.4)	0.895
Smoking, n (%)	349 (56.5)	440 (53.3)	0.359
Double platelet inhibitor therapy, n (%)	219 (35.4)	363 (44.0)	0.001
Creatinine median (Q1, Q3)	85 (72, 102)	88 (75, 105)	0.004*
Dead at follow-up, n (%)	170 (27.5)	420 (50.9)	< 0.001

200	Table 2. Demographic characteristics of the individuals who received a conherence win	and ft
298	Table 3: Demographic characteristics of the individuals who received a saphenous vein	gratt
		0

* Mann-Whitney U test was used. T-test was used for continuous variables and Chi-squared
test for categorical variables. Values are presented as mean ± standard deviation for normal
distributed variables, median (Q1, Q3) for non-normal distributed variables, or n (%). Ages
and times are given in years. Creatinine is given in micromole/L.

304 Table 4: Operative and procedural characteristics of the individuals who received a

305 saphenous vein graft

No-touch	Conventional	p-value	
618	825		
908	1656		
3.5 ± 1.1	3.5 ± 1.0	0.373	
60 (50, 60)	60 (50, 65)	< 0.001*	
		0.916	
501 (81.1)	667 (80.8)		
117 (18.9)	158 (19.2)		
	618 908 3.5 ± 1.1 60 (50, 60) 501 (81.1)	618 825 908 1656 3.5 ± 1.1 3.5 ± 1.0 $60 (50, 60)$ $60 (50, 65)$ $501 (81.1)$ $667 (80.8)$	

306 * Mann-Whitney U test was used. Values are presented as mean ± standard deviation for

307 normal distributed variables, median (Q1, Q3) for non-normal distributed variables, or n (%).

308 EF: ejection fraction. MI: myocardial infarction.

- 310 Table 5: Patency rate per patient of no-touch and conventional vein grafts, and patency of
- 311 arterial grafts divided by type of vein graft

Patient characteristics	No-touch	Conventional	p-value
No. of patients	618	825	
Patency/patient of Vein Grafts, %	70.7	46.7	< 0.001
Patency/patient of Arterial grafts, %	86.4	86.3	0.954
Patency/patient of LITA, %	98.4	95.9	0.006

312 Values are presented as %. LITA: left internal thoracic artery.

Table 6: Patency in no-touch and conventional vein grafts divided by type of graft

Patient characteristics	No-touch	Conventional	p-value
No. of Grafts	908	1656	
Graft Patency	75.9	63.5	< 0.001
Single	75.6	62.8	< 0.001
Sequential	76.0	65.3	< 0.001

315 Values are presented as %.


- 317 Table 7: Patency of no-touch and conventional vein grafts divided by territory of distribution
- 318 and sub-divided by graft type (single or sequential)

Patient characteristics	No-touch	Conventional	p-value
To LAD	58/70 (82.9)	45/66 (68.2)	0.046
Single	30/36 (83.3)	35/49 (71.4)	0.201
Sequential	28/34 (82.4)	10/17 (58.8)	0.093*
To DA	317(360 (88.1)	353/519 (68.0)	< 0.001
Single	44/54 (81.5)	160/273 (58.6)	0.002
Sequential	273/306 (89.2)	193/246 (78.5)	< 0.001
То МА	402/468 (85.9)	529/673 (78.6)	0.002
Single	90/104 (86.5)	270/339 (79.6)	0.115
Sequential	312/364 (85.7)	259/334 (77.5)	0.005
To RCA	285/404 (70.5)	355/623 (57.0)	< 0.001
Single	183/256 (71.5)	307/549 (55.9)	< 0.001
Sequential	102/148 (68.9)	48/74 (64.9)	0.543


319 Values are presented as n, (%). LAD: left anterior descending, DA: diagonal artery,

320 MA: marginal artery, RCA: right coronary artery. * Fisher's exact test.

322 Figure 1



323



325 no-touch graft; PCI: percutaneous coronary intervention; SVG: saphenous vein graft.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.19.24303064; this version posted February 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

326 **References**

- 3271.WHO. The top 10 causes of death. 2020 [cited Available from: https://www.who.int/news-328room/fact-sheets/detail/the-top-10-causes-of-death
- Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG,
 Guyton RA, Hollenberg SM, et al. 2015 ACC/AHA/SCAI Focused Update on Primary
 Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction:
 An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
 and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial
 Infarction. J Am Coll Cardiol 2016;67(10):1235-50.
- Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet
 J-P, Falk V, Head SJJEhj. 2018 ESC/EACTS guidelines on myocardial revascularization.
 2019;40(2):87-165.
- 3384.Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PKJJotACoC.339ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary340revascularization in patients with stable ischemic heart disease: a report of the American341College of Cardiology appropriate use criteria task force, American Association for Thoracic342Surgery, American Heart Association, American Society of Echocardiography, American343Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions,344Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons.
- 2017;69(17):2212-41.
 5. Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B,
 Stefanini GG, Sidhu MSJJotACoC. Long-term survival following multivessel revascularization
 in patients with diabetes: the FREEDOM follow-on study. 2019;73(6):629-38.
- Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ,
 Rosenberg Y, Solomon SD, et al. Strategies for multivessel revascularization in patients with
 diabetes. N Engl J Med 2012;367(25):2375-84.
- Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes
 DR, Jr., Morel MA, Van Dyck N, et al. Coronary artery bypass graft surgery versus
 percutaneous coronary intervention in patients with three-vessel disease and left main
 coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet
 2013;381(9867):629-38.
- 3578.Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman358TE, van den Brand M, Bass EJ, et al. Percutaneous coronary intervention versus coronary-359artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360(10):961-72.
- 360
 9. Thuijs D, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, Holmes DR, Jr., Curzen
 361
 N, Davierwala P, Noack T, et al. Percutaneous coronary intervention versus coronary artery
 362
 bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year
 363
 follow-up of the multicentre randomised controlled SYNTAX trial. Lancet
 364
 2019;394(10206):1325-34.
- 365 10. Souza D. A new no-touch preparation technique. Technical notes. Scand J Thorac Cardiovasc
 366 Surg 1996;30(1):41-4.
- Ramos De Souza D, Dashwood MR, Samano N. Saphenous vein graft harvesting and patency:
 No-touch harvesting is the answer. J Thorac Cardiovasc Surg 2017;154(4):1300-1.
- Samano N, Dashwood M, Souza D. No-touch vein grafts and the destiny of venous
 revascularization in coronary artery bypass grafting-a 25(th) anniversary perspective. Ann
 Cardiothorac Surg 2018;7(5):681-5.
- Johansson BL, Souza DS, Bodin L, Filbey D, Loesch A, Geijer H, Bojö L. Slower progression of
 atherosclerosis in vein grafts harvested with 'no touch' technique compared with
 conventional harvesting technique in coronary artery bypass grafting: an angiographic and
 intravascular ultrasound study. Eur J Cardiothorac Surg 2010;38(4):414-9.

376	14.	Samano N, Geijer H, Liden M, Fremes S, Bodin L, Souza D. The no-touch saphenous vein for
377	14.	coronary artery bypass grafting maintains a patency, after 16 years, comparable to the left
378		internal thoracic artery: A randomized trial. J Thorac Cardiovasc Surg 2015;150(4):880-8.
379	15.	Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C,
380	15.	Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in
381		Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4(10):e297.
382	16	
382 383	16.	Souza DS, Dashwood MR, Tsui JC, Filbey D, Bodin L, Johansson B, Borowiec J. Improved
		patency in vein grafts harvested with surrounding tissue: results of a randomized study using
384	47	three harvesting techniques. Ann Thorac Surg 2002;73(4):1189-95.
385	17.	Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen
386		MG, DiMaio JM, Don CW, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery
387		Revascularization: Executive Summary: A Report of the American College of
388 389		Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
	10	Circulation 2022;145(3):e4-e17.
390 391	18.	Swedeheart. 2020 [cited 2020 30 November 2020]. Available from:
	10	https://www.ucr.uu.se/swedeheart/.
392	19.	Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft
393 204		fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and
394 395	20	reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28(3):616-26.
	20.	Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B,
396		Ellis N, Anderson RJ, et al. Long-term patency of saphenous vein and left internal mammary
397		artery grafts after coronary artery bypass surgery: results from a Department of Veterans
398	24	Affairs Cooperative Study. J Am Coll Cardiol 2004;44(11):2149-56.
399 400	21.	Shah PJ, Gordon I, Fuller J, Seevanayagam S, Rosalion A, Tatoulis J, Raman JS, Buxton BF.
400 401		Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402
401		symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg
	22	2003;126(6):1972-7.
403 404	22.	Deb S, Singh SK, de Souza D, Chu MWA, Whitlock R, Meyer SR, Verma S, Jeppsson A, Al-Saleh
404 405		A, Brady K, et al. SUPERIOR SVG: no touch saphenous harvesting to improve patency
405		following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449).
400	22	J Cardiothorac Surg 2019;14(1):85.
407	23.	Samano N, Pinheiro BB, Souza D. Surgical Aspects of No-Touch Saphenous Vein Graft
		Harvesting in CABG: Clinical and Angiographic Follow-Up at 3 Months. Braz J Cardiovasc Surg
409 410	24	2019;34(1):98-100.
410	24.	Souza DS, Johansson B, Bojö L, Karlsson R, Geijer H, Filbey D, Bodin L, Arbeus M, Dashwood
412		MR. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: results of a randomized
412		longitudinal trial. J Thorac Cardiovasc Surg 2006;132(2):373-8.
413	25.	Tian M, Wang X, Sun H, Feng W, Song Y, Lu F, Wang L, Wang Y, Xu B, Wang H, et al. No-
415	23.	Touch Versus Conventional Vein Harvesting Techniques at 12 Months After Coronary Artery
415		Bypass Grafting Surgery: Multicenter Randomized, Controlled Trial. Circulation
417		2021;144(14):1120-9.
418	26.	Ferrari G, Geijer H, Cao Y, Graf U, Bojö L, Carlsson R, Souza D, Samano N. Long-term results
419	20.	
419		of percutaneous coronary intervention in no-touch vein grafts are significantly better than in conventional vein grafts. Perfusion 2024:2676591241230012.
420	27.	Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck
421	21.	MR, Galbraith M, et al. 2023 ESC Guidelines for the management of acute coronary
422		syndromes. Eur Heart J 2023.
423		synatomes. Eur meart 3 2023.
424		